AnaptysBio Inc. is a clinical-stage biotechnology company that focuses on developing innovative immunology therapeutics aimed at addressing unmet medical needs in autoimmune and inflammatory diseases. The company employs advanced immune cell modulation technologies, particularly through the development of best-in-class antibodies. One of their key products, ANB032, is a non-depleting antibody that targets the BTLA co-inhibitory receptor, which plays a crucial role in regulating T cell activity. By inhibiting activated T cell proliferation and reducing inflammatory cytokine secretion, ANB032 aims to restore immune balance and has shown potential in treating a variety of systemic inflammatory diseases.

Another significant therapeutic candidate from AnaptysBio is Rosnilimab, a PD-1 agonist designed to specifically target activated T cells. This antibody works by depleting PD-1 high T cells, thereby reducing their migration, proliferation, and cytokine secretion, which are critical factors in the pathogenesis of autoimmune diseases. Additionally, Imsidolimab, an IL-36 receptor antagonist, has demonstrated effectiveness in treating generalized pustular psoriasis. These innovative approaches highlight AnaptysBio's commitment to restoring immune homeostasis and providing differentiated therapeutic outcomes in the management of complex inflammatory conditions.

United States

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

Immune System Diseases

Lung Diseases

Skin Diseases

AnaptysBio Inc

Cancer

Endometrial cancer

Solid tumor/s

Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth
<a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwidqpjHtJXwAhWNHM0KHXrSAzsQFjAAegQIAhAD&amp;url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F761174s000lbl.pdf&amp;usg=AOvVaw1l_nsC_PpWYpEfAHwsWfdD">Source</a>

JEMPERLI (Dostarlimab-gxly)

Acne

EGFRi-mediated skin toxicity

Generalized pustular psoriasis

Hidradenitis suppurativa

Ichthyosis

Palmoplantar pustulosis

Imsidolimab, previously known as ANB019, is an antibody that inhibits &nbsp;the function of the interleukin-36-receptor, or IL-36R, which we are &nbsp;initially developing as a potential first-in-class therapy for patients &nbsp;suffering from generalized pustular psoriasis (GPP), palmoplantar &nbsp;pustulosis (PPP), EGFRi-mediated skin toxicity, ichthyosis, hidradenitis &nbsp;suppurativa and acne.

Imsidolimab (ANB019) (anti-IL-36R)

Ovarian cancer

Jemperli (dostarlimab) + Zejula (niraparib) 

Non-small cell lung carcinoma

Dostarlimab

Dostarlimab+ belrestotug

Autoimmune disease

Rheumatoid arthritis

ANB030 is an antibody that binds PD-1 in an agonistic manner, leading to reduced T cell activity and anti-inflammatory effects in vivo.&nbsp;&nbsp; &nbsp;PD-1 is a key inhibitory immune checkpoint receptor expressed by &nbsp;activated T cells.&nbsp; PD-1 activity contributes to downregulation of T &nbsp;cell mediated immune responses in healthy individuals.

Rosnilimab (ANB030) 

Ulcerative colitis

Rosnilimab (ANB030) (PD-1 agonist)

Inflammatory disease

ANB033 is a novel anti-CD122 antagonist that targets the shared common beta subunit of the receptors for IL-15 and IL-2

ANB033 (anti-CD122 antagonist antibody)

ANB101 is a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs).

ANB101 (BDCA2 modulator)

Atopic disorder

Chronic rhinosinusitis

Nasal polyps

Etokimab, previously known as ANB020, is an antibody that inhibits the activity of IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases. We believe IL-33 may directly mediate release of disease-associated downstream cytokines, which recruit pro-inflammatory cells that mediate atopic disease. Because etokimab inhibits IL-33 function, and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism may have advantages in the treatment of certain atopic diseases over competing agents that block only a subset of the downstream cytokines responsible for atopic diseases. The role of IL-33 signaling in atopic diseases has been genetically validated through human studies published in medical literature.

Etokimab (ANB020) Anti-IL-33

Alopecia areata

Skin disease/disorder

Vitiligo

Rosnilimab (ANB030) (PD-1 agonist) 

Atopic dermatitis

ANB032, its investigational wholly owned BTLA agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation and reduction in inflammatory cytokine secretion (Th1, Th2, Th17) compared to Lilly BTLA agonist

AnaptysBio Inc

Company Details